BMEA

NASD Biomea Fusion Inc
Oct 9, 2026 · 9:09 AM ET LAST TRADE Market Closed

$1.37 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.37

YTD change
+10.48%
vs 20-day SMA
-8.76%
vs 200-day SMA
-3.11%

Price ranges

Previous day
$1.30 $1.38
open $1.32 close $1.37
+$0.05 (+3.79%)
Today
$0.00 $0.00
$1.37
Past week
$1.22 $1.38
from $1.30 now $1.37
+$0.07 (+5.38%)
Past month
$1.22 $1.93
from $1.70 now $1.37
-$0.33 (-19.41%)
This year
$1.03 $2.24
from $1.24 now $1.37
+$0.13 (+10.48%)

Price & Performance

-0.48 (-25.95%) / 6M

$1.05$1.46$1.88$2.30Apr 9Jul 10Oct 8

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 96.9% away from all-time highs of $43.69
  • BMEA is up 10% since the beginning of the year
  • BMEA is down 23% over the past 12 months
  • BMEA is down 19% over the past 1 month
  • 21% of all BMEA investors are betting against BMEA

BMEA reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is -23.5%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.12
Earnings momentum +45.5% Quarterly EPS growth
Quarterly change +45.5%

Valuation

P/E ratio N/A
Enterprise value $64.8M
Beta 1.59

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$35.2M
Debt$877.0
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $99.3M

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $407.44 -1.37%
MRNA Moderna, Inc. $197.00 +0.26%
RVMD Revolution Medicines, Inc. $188.12 -6.35%
ROIV Roivant Sciences Ltd. $34.21 -1.55%
BNTX BioNTech SE Sponsored ADR $92.06 -3.35%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.